Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

Kasper Recourt; Peter de Boer; Rob Zuiker; Remy Luthringer; Justine Kent; Peter van der Ark; Ilse Van Hove; Joop van Gerven; Gabriel Jacobs; Luc van Nueten; Wayne Drevets

doi:10.1038/s41398-019-0585-4

Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

Transl Psychiatry. 2019 Oct 2;9(1):240. doi: 10.1038/s41398-019-0585-4.

Authors

Kasper Recourt^{1

2}, Peter de Boer³, Rob Zuiker⁴, Remy Luthringer⁵, Justine Kent⁶, Peter van der Ark³, Ilse Van Hove³, Joop van Gerven^{4

7}, Gabriel Jacobs^{4

7}, Luc van Nueten³, Wayne Drevets³

Affiliations

¹ Centre for Human Drug Research, Leiden, The Netherlands. Krecourt@chdr.nl.
² Leiden University Medical Center, Leiden, The Netherlands. Krecourt@chdr.nl.
³ Janssen Research and Development, Division of Janssen Pharmaceutica N.V., Beerse, Belgium.
⁴ Centre for Human Drug Research, Leiden, The Netherlands.
⁵ Minerva Neurosciences, Waltham, MA, USA.
⁶ Sunovion, Fort Lee, NJ, USA.
⁷ Leiden University Medical Center, Leiden, The Netherlands.

Abstract

In the original Article, Tables two and three had formatting issues which affected their clarity. This has been corrected in the PDF and HTML versions of this Article.

Publication types

Published Erratum